La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Leap Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Leap Therapeutics..

Leap Therapeutics (NASDAQ:LPTX) Azioni, Catena delle Opzioni

LEAP THERAPEUTICS INC

Leap Therapeutics

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

WIIM

MOGO

Mogo shares are trading higher after the company announced a $50 million bitcoin treasury authorization.

<h3>Gainers</h3>
<ul>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) shares rose 22.2% to $0.28 during Wednesday's pre-market session. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) stock moved upwards by 12.42% to $0.9. The market value of their outstanding shares is at $11.0 million. </li>
<li>Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) stock increased by 8.01% to $12.0. The market value of their outstanding shares is at $544.5 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares moved upwards by 5.95% to $2.85. The market value of their outstanding shares is at $111.7 million. </li>
<li>JX Luxventure Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) shares moved upwards by 5.62% to $1.69. The company's market cap stands at $6.4 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock rose 5.49% to $0.95. The company's market cap stands at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dogness (Intl) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) shares fell 24.9% to $9.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $181.4 million. </li>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares fell 13.39% to $0.85. The company's market cap stands at $52.1 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares fell 12.88% to $0.14. The company's market cap stands at $8.3 million. </li>
<li>Playboy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) stock decreased by 5.57% to $1.51. The company's market cap stands at $150.3 million. </li>
<li>Lead Real Estate Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) stock fell 5.56% to $1.7. The market value of their outstanding shares is at $24.5 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock decreased by 5.0% to $0.25. The company's market cap stands at $10.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BALY

DOGZ

ECDA

FLYE

KXIN

MAMO

NAAS

PLBY

PMNT

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock rose 24.9% to $3.11 during Wednesday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares rose 12.58% to $24.69. The company's market cap stands at $143.8 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 11.72% to $1.62. The company's market cap stands at $6.6 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares increased by 11.57% to $1.35. The market value of their outstanding shares is at $3.8 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares rose 11.53% to $0.79. The market value of their outstanding shares is at $38.4 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 11.11% to $1.1. The company's market cap stands at $4.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 30.2% to $39.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares declined by 27.32% to $1.49. The company's market cap stands at $8.9 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) stock decreased by 12.31% to $3.35. The market value of their outstanding shares is at $69.8 million. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock declined by 10.86% to $0.41. The market value of their outstanding shares is at $104.9 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares fell 10.71% to $0.73. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares decreased by 9.93% to $1.27. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNTA

MBIO

MODD

NIVF

REVB

SBFM

SCNI

SNGX

SONN

VXRT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Earlyworks Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) shares moved upwards by 80.0% to $3.42 during Wednesday's pre-market session. The company's market cap stands at $5.7 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock rose 25.52% to $0.08. The market value of their outstanding shares is at $1.0 million. </li>
<li>Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) shares moved upwards by 15.5% to $0.42. The market value of their outstanding shares is at $11.3 million. </li>
<li>Royalty Management Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCO#NASDAQ">RMCO</a>) stock increased by 13.84% to $1.48. The market value of their outstanding shares is at $19.4 million. </li>
<li>Greenbrier Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) stock moved upwards by 13.82% to $53.5. The company's market cap stands at $1.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock increased by 10.44% to $0.25. The company's market cap stands at $32.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) stock decreased by 46.1% to $6.0 during Wednesday's pre-market session. The market value of their outstanding shares is at $20.0 million. </li>
<li>Pinnacle Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFAI#NASDAQ">PFAI</a>) stock declined by 20.51% to $1.93. The company's market cap stands at $28.4 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares declined by 9.24% to $1.77. The company's market cap stands at $4.8 million. </li>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) stock declined by 8.79% to $15.37. The company's market cap stands at $1.6 billion. </li>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) stock fell 8.3% to $1.88. The company's market cap stands at $45.1 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares decreased by 6.49% to $1.01. The market value of their outstanding shares is at $120.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

CYCU

ELWS

LGCL

PFAI

POLA

RMCO

SCWO

WETO

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock increased by 45.4% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $65.4 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares moved upwards by 15.87% to $14.83. The company's market cap stands at $22.4 million. </li>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) stock moved upwards by 14.03% to $2.25. The company's market cap stands at $119.1 million. </li>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) stock rose 12.63% to $51.81. The company's market cap stands at $278.9 million. </li>
<li>Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) stock rose 9.95% to $20.44. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock increased by 8.91% to $0.17. The company's market cap stands at $9.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares decreased by 18.5% to $0.3 during Wednesday's pre-market session. The company's market cap stands at $23.4 million. </li>
<li>ClearOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>) shares declined by 16.99% to $8.7. The company's market cap stands at $18.1 million. </li>
<li>Argo Blockchain plc - 8.75% Senior Notes due 2026 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBKL#NASDAQ">ARBKL</a>) stock declined by 15.17% to $2.65. </li>
<li>Youxin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) shares declined by 13.67% to $0.43. The company's market cap stands at $16.7 million. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares fell 7.81% to $6.5. The market value of their outstanding shares is at $67.0 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock decreased by 7.73% to $2.15. The market value of their outstanding shares is at $49.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

Argo Blockchain plc - 8.75% Senior Notes due 2026

ARBKL

BMNR

BTCS

BTOG

CLRO

GRYP

TZUP

VRNT

YAAS

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

News

Dividends

NTRB

Nutriband Board Approves 25% Preferred Stock Dividend; Shareholders Of Record On Jul. 25 Will Receive One Preferred Share For Every Four Common Shares Held

Board-Approved Allocation Reflects Long-Term Conviction in Bitcoin as a Strategic Reserve Asset and Foundation for Innovation Across Treasury and Product Strategy
Strategic Alignment Across Core Businesses of Wealth, Payments and Lending
Company Adopts Bitcoin as Corporate Hurdle Rate
Mogo Inc. ("Mogo" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#TSX">MOGO</a>), a leading Canadian digital wealth and lending platform, today announced that its Board of Directors has authorized the allocation of up to $50 million to Bitcoin as part of the Company's long-term capital preservation and product innovation strategy. The move marks a significant step in Mogo's strategic alignment with Bitcoin, integrating it across treasury policy and its core operating platform.

TSX:MOGO

Mogo Board Authorizes Allocation Of Up To $50M To Bitcoin As Part Of Long-Term Capital Preservation And Product Innovation Strategy

Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched NIOPEG&#xAE;, the Company's first Biosimilar drug on the market.
NIOPEG&#xAE; is a Biosimilar comparable to the reference biologic drug NEULASTA&#xAE; (Pegfilgrastim). Like NEULASTA&#xAE;, NIOPEG&#xAE; is a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving chemotherapy. NIOPEG&#xAE; is available in a prefilled syringe of 6mg/0.6mL.
As of 2024, the global market size for NEULASTA&#xAE; and its biosimilars was estimated at $4.5 billion, with projections suggesting it could reach $9.2 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.5% (Verified Market Reports). The growth is largely driven by rising global cancer incidence and chemotherapy use.
The Canadian market for NEULASTA&#xAE; and its Biosimilars is smaller but still significant due to high biologics spending. Biologic drug sales in Canada reached $10 billion in 2020, accounting for about one-third of total pharmaceutical spending (<a href="https://pr.report/bzpa">www.canada.ca</a>). NEULASTA&#xAE; is one of the key biologics used in oncology, and its biosimilars have been gaining traction, especially after provincial switching policies were introduced to encourage cost savings.
Although Canada represents a smaller slice of the global market, its per capita biologics spending ranks among the highest in the OECD (Organisation for Economic Co-operation and Development), making it a valuable market for both branded and biosimilar products.
"The launch of NIOPEG&#xAE; as a biosimilar to NEULASTA&#xAE; represents a strategic milestone in our growth trajectory," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. By entering the high value-added biologics market with a cost-effective and clinically equivalent alternative, we are strengthening our portfolio, expanding our addressable market, and creating new revenue streams. This reinforces our commitment to delivering sustainable value to patients, the healthcare system, and our shareholders alike."

Biotech

General

Sunshine Biopharma Announces That Its Wholly Owned Canadian Subsidiary, Nora Pharma, Has Launched Niopeg, The Company's First Biosimilar Drug

MCHP

Microchip Partners With Nippon Chemi-Con And NetVision To Simplify Adoption And Acceleration Of ASA-ML For Advanced Driver-Assistance Systems

UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) raises FY2025 GAAP EPS guidance from $7.30-$7.70 to $7.60-$8.00 vs $7.56 analyst estimate. Affirms FY2025 sales outlook from $2.422 billion-$2.432 billion to $2.422 billion-$2.432 billion vs $2.428 billion estimate.

Guidance

UniFirst Raises FY2025 GAAP EPS Guidance from $7.30-$7.70 to $7.60-$8.00 vs $7.56 Est; Affirms FY2025 Sales Guidance of $2.422B-$2.432B vs $2.428B Est

Zuanic &amp; Associates analyst Pablo Zuanic reiterates MariMed (NEOD: MRMD) from Overweight to Overweight.

Reiteration

Analyst Ratings

Zuanic & Associates Reiterates Overweight on MariMedto Overweight

Agreement Targets Southeast Asia, South America, Hong Kong&nbsp;SAR and Macau SAR Markets
SHANGHAI, July 2, 2025 /PRNewswire/ --&nbsp;U Power Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) (the "Company" or "U Power"), a provider of comprehensive electric vehicle ("EV") battery-swapping solutions with a vision of becoming a smart energy grid solutions provider, today announced the signing of a Memorandum of Understanding (the "MOU") with Beijing Foton International Trade Co., Ltd. ("Beijing Foton"), a wholly-owned subsidiary of <a href="https://www.foton.com.cn/">Beijing Foton Motor Co., Ltd</a>. ("Foton Motor"), a leading commercial vehicle manufacturer in China.
Pursuant to the MOU, the two parties will jointly promote battery-swapping compatible electric heavy trucks, buses and vans in the Southeast Asia, South America, Hong Kong SAR, and Macau SAR markets. U Power will provide technological support to enable incorporation of battery-swapping capabilities on Beijing Foton vehicles, development and testing of battery-swapping stations to serve electric vehicle models, as well as connection of vehicles with its battery-bank ecosystem. Additionally, Beijing Foton will gather and share performance data such as battery charging, health and capacity records. Both parties could potentially expand the agreement to include additional cooperation opportunities in the future.

UCAR

U Power and Beijing Foton Sign MOU To Expand EV Battery-Swapping Solutions In Southeast Asia, South America, And SAR Markets

Contracts

Forge GlobalBon Announces Sales Distribution Agreement With Huahai Keyuan, Under Which Huahai Keyuan Will Market, Sell And Distribute BON's Prebiotic Series Products In Chinese Market; Total Contract Value Up To $16M

USAU

U.S. Gold Added To Russell 3000 And Russell 2000 Indexes

CareCloud, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>, CCLDO))) ("CareCloud" or the "Company"), a leader in AI-driven healthcare technology solutions for medical practices and health systems nationwide, today announced that it has been added to the Russell Microcap&#xAE; Index, effective at the open of U.S. markets on June 30, 2025, as part of the Russell indexes' annual reconstitution based on market capitalization, public float, and related criteria. The inclusion underscores growing recognition of CareCloud's momentum in the healthcare technology sector.
During Q2, the price of the Company's common stock increased by approximately 70%. Key developments during the first half of 2025 included the launch of CareCloud's new&nbsp;AI Center of Excellence, the&nbsp;resumption of acquisition activities&nbsp;in targeted growth areas, the conversion of approximately 3.5 million shares of the Company's Series A Preferred Stock into Common Stock on March 6, 2025 and a&nbsp;strong cash position of approximately $10 million&nbsp;at the end of Q2 2025.

CCLD

CareCloud Added to Russell Microcap Index

Name change reflects company's leadership position with its cryptocurrency treasury reserve strategy focused on the HYPE token
Company to commence trading on Nasdaq under the symbol "HYPD" effective July 3rd
Also announces official launch of the Kinetiq x Hyperion validator
Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) ("Eyenovia" or the "Company"), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced that it is rebranding and changing its corporate name to Hyperion DeFi, Inc. Concurrent with the name change, the Company's shares will begin trading under the new ticker symbol "HYPD" on the Nasdaq Capital Market at the start of trading on July 3, 2025.
The name change reflects the Company's recent launch of its cryptocurrency treasury reserve strategy focused on the HYPE token, which is native to the decentralized digital asset exchange and Layer-1 blockchain, Hyperliquid.

EYEN

Eyenovia Announces Corporate Name Change To Hyperion DeFi. Company Will Trade Under Symbol HYPD On Nasdaq, Effective July 3, 2025

UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) reported quarterly earnings of $2.17 per share which beat the analyst consensus estimate of $2.09 by 3.93 percent. This is a 0.91 percent decrease over earnings of $2.19 per share from the same period last year. The company reported quarterly sales of $610.778 million which missed the analyst consensus estimate of $614.510 million by 0.61 percent. This is a 1.23 percent increase over sales of $603.328 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

UniFirst Q3 Adj. EPS $2.17 Beats $2.09 Estimate, Sales $610.778M Miss $614.510M Estimate

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company" or "DeFi Dev Corp."), the first public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced the pricing of its upsized private offering of $112.5 million aggregate principal amount of 5.5% convertible senior notes due 2030 (the "Convertible Notes"), to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").
Key Elements of the Transaction:
<ul>
<li>$112.5 million 5.5% Convertible Notes offering, due 2030.</li>
<li>Approximately 10% conversion premium to the $21.01 closing price on July 1, 2025.</li>
<li>Prepaid forward stock purchase transaction of approximately $75.6 million of shares of the Company's common stock in connection with the offering to facilitate hedging by certain investors.</li>
</ul>
The Company has granted the initial purchasers of the Convertible Notes an option to purchase, for settlement within a 7-day period beginning on, and including the date on which the Convertible Notes are first issued, up to an additional $25 million aggregate principal amount of the Convertible Notes. The offering is expected to close on July 8, 2025, subject to satisfaction of customary closing conditions.

Offerings

DFDV

DeFi Development Corp. Prices Upsized $112.5M Convertible Note Offering Due 2030, Tied To Solana Treasury Strategy

Jefferies analyst Corey Tarlowe upgrades Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Hold to Buy and raises the price target from $135 to $150.

Upgrades

Price Target

ROST

Jefferies Upgrades Ross Stores to Buy, Raises Price Target to $150

Cycurion To Service As authorized Reseller Of AgileBlue's Cybersecurity Solutions

Press Releases

Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Leap Therapeutics Reports First Quarter 2025 Financial Results

Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives

Comments

Leap Therapeutics

Leap Therapeutics (LPTX) Opzioni

Leap Therapeutics (NASDAQ:LPTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO